Avidity Biosciences

Avidity Biosciences develops and markets oligonucleotide-based therapeutics to treat muscle disorders.

Business Model:

Revenue: $8.4M

Employees: 51-200

Detailed Avidity Biosciences Information

Geographic Data

Avidity Biosciences headquarters map

Address: 10975 N Torrey Pines Road

City: La Jolla

State: CA

Zip: 92037

Country: US

Financial Info

Stage:

series c

Raised Last:

$100M

Raised Total:

$140M

Metrics

1,412,143Website Global Rank

19,251Website Monthly Traffic

Twitter Followers

Description

Avidity Biosciences develops and markets oligonucleotide-based therapeutics to treat muscle disorders.

Contact Phone:
+18584017900

Contact Email:

Avidity Biosciences went public on 6/11/2020 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
6/11/2020

IPO Valuation:
$636M

Ticker Symbol:
RNA

IPO Price:
$18/share

Amount Raised:
$298M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
10/2018 Series B $0 Takeda
Alethea Capital Management
Alexandria Real Estate Equities
Brace Pharma
EcoR1 Capital
F-Prime Capital
Moore Venture Partners
Tavistock Life Sciences
Takeda
Alethea Capital Management
Alexandria Real Estate Equities
Brace Pharma
EcoR1 Capital
F-Prime Capital
Moore Venture Partners
Tavistock Life Sciences
11/2019 Series C $0 Perceptive Advisors
Takeda Ventures
Eli Lilly
Logos Capital
Partner Fund Management
CureDuchenne Ventures
RTW Investments LLC
Cormorant Asset Management
Brace Pharma
Alethea Capital Management
RTW Investments LLC
Perceptive Advisors
Takeda Ventures
Eli Lilly
Logos Capital
Partner Fund Management
CureDuchenne Ventures
RTW Investments LLC
Cormorant Asset Management
Brace Pharma
Alethea Capital Management
RTW Investments LLC
12/2022 Post-IPO Equity $207M
12/2016 Series B $16M Takeda Ventures, Inc.
Alethea Capital
Alexandria Real Estate Equities
BracePharma
EcoR1 Capital
F-Prime Capital
Moore Venture Partners
Tavistock Life Sciences
6/2020 IPO $259.2M
10/2014 Convertible Note $6M TPG Biotech
Brace Pharma
Partner Fund Management, L.P
4/2019 Venture Round 1 $15M Eli Lilly
Eli Lilly
2/2014 Series A $9.1M
10/2018 Equity -
1/2014 Venture Round 1 - Eight Roads Ventures
Eight Roads Ventures
11/2019 Series C 10 $100M RTW Investments
CureDuchenne
Logos Capital
Perceptive Advisors LLC
ST Pharm
Alethea Capital
Alexandria Venture Investments
Boxer Capital
Brace Pharma Capital
EcoR1 Capital
Partner Fund Management
Takeda Ventures
Eli Lilly and Company
Perceptive Advisors
Takeda Ventures
Eli Lilly
Logos Capital
Partner Fund Management
CureDuchenne Ventures
RTW Investments LLC
Cormorant Asset Management
Brace Pharma
Alethea Capital Management
RTW Investments LLC
10/2018 Equity - CureDuchenne
CureDuchenne
10/2018 Series B 8 $16M Takeda
Takeda
1/2014 Venture Round 1 - Eight Roads Ventures
Eight Roads Ventures
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research